OncoMatch/Clinical Trials/NCT05701306
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
Is NCT05701306 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including APG-115 and APG-2575 for neuroblastoma.
Treatment: APG-115 · APG-2575 — An open, non-randomized Phase Ib-II trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory neuroblastoma or solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroblastoma
Tumor Agnostic
Demographics
Prior therapy
Cannot have received: MDM2 inhibitor
Received MDM2 inhibitors or BCL-2 inhibitors.
Cannot have received: BCL-2 inhibitor
Received MDM2 inhibitors or BCL-2 inhibitors.
Lab requirements
Blood counts
Kidney function
Liver function
Have adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05701306 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MDM2 inhibitor, BCL-2 inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages